Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Non-Current Debt (2020 - 2021)

Inhibikase Therapeutics (IKT) has 2 years of Non-Current Debt data on record, last reported at $248911.0 in Q2 2021.

  • On a quarterly basis, Non-Current Debt changed N/A to $248911.0 in Q2 2021 year-over-year; TTM through Jun 2021 was $248911.0, a N/A change, with the full-year FY2020 number at $276461.0, changed N/A from a year prior.
  • Non-Current Debt reached $248911.0 in Q2 2021 per IKT's latest filing, roughly flat from $248911.0 in the prior quarter.
  • Over the last five years, Non-Current Debt for IKT hit a ceiling of $276461.0 in Q4 2020 and a floor of $248911.0 in Q1 2021.